The three major methods in MegaKaryon's production of platelets based on iPS cells include introducing three different genes into an iPS cell, establishing megakaryocyte precursor cells, freezing these precursor cells, and irradiating the cells to ensure they a sterile/clean. Additionally, Megakaryon is internationally the first and only company that owns proprietary technology to manufacture large quantities of iPS cell-originated platelets.
HOW MEGAKARYON USES IPS CELLS TO PRODUCE PLATELETS
- Three genes are introduced into an iPS cell, establishing megakaryocyte precursor cells.
- These three genes have the functions of multiplying cells, suppressing cell aging and preventing cell death.
- The result is a precursor cell that can be safely multiplied.
- These precursor cells are frozen and stored for prolonged periods of time.
- This allows MegaKaryon to produce and provide varying quantities of platelets on an as-needed basis.
- This is significant because, previously, platelets could only be stored for four days and needed to be constantly resupplied through human donation.
- The Kyoto Development center has a CleanRoom.
- The CleanRoom classification standards require specific particle count measurements and calculations to classify the cleanliness level.
- In this room, irradiation of the cells inactivates any cells which are not platelets.
- 2019/02/04: The Boston Hospital Magazine published an article about the success of their partnership with Megakaryon.
- 2018/06/13: Megakaryon was chosen for a J-Startup Program.
- 2018/03/08: The company was named on Forbes.
- 2017/12/25: MegaKaryon raised ¥3,700 million $34.35 million) in private funding.
- 2017/06/28: It was announced that MegaKaryon would be featured at 2017 Japan US Innovation Awards Symposium at Stanford.
- 2016/05/01: MegaKaryon announced the expansion of their Kyoto offices and lab.
- 2016/04/12: AMED, which is the Japan Agency for Medical Research and Development, adopted MegaKaryon's project.
- 2015/11/25: MegaKaryon began a collaborative research project with Harvard University and the Boston Children's Hospital.
- 2015/03/20: The company raised ¥2,540 million ($23.58 million) in private shares.
- 2015/03/19: The Kansai National Strategic Special Zone recognizes the company as a Designated Core Business.
- 2009: Professors Nakauchi and Eto discover a method to proliferate megakaryocytes and induce platelet production that forms the basis of mass production of platelets from iPS cells."